Literature DB >> 27015109

Risk of Cerebrovascular Accidents and Ischemic Heart Disease in Cutaneous Lupus Erythematosus: A Population-Based Cohort Study.

Abha G Singh1, Cynthia S Crowson2, Siddharth Singh3, Mark Denis, P Davis2, Hilal Maradit-Kremers2, Eric L Matteson2, Vaidehi R Chowdhary4.   

Abstract

OBJECTIVE: It is unclear whether isolated cutaneous lupus erythematosus (CLE) affects cardiovascular risk. We estimated the cumulative incidence and mortality of cardiovascular diseases in a population-based CLE cohort and compared the risk with a matched non-CLE cohort.
METHODS: All incident cases of CLE in Olmsted County, Minnesota, between 1965 and 2005 were followed until December 2013. The cumulative incidence of cerebrovascular accidents (CVAs [including stroke and transient ischemic attack]), ischemic heart disease (IHD [including coronary artery disease, myocardial infarction, and angina pectoris]), heart failure, and peripheral arterial disease (PAD) was derived and compared to an age-, sex-, and calendar year-matched non-CLE cohort using Cox models.
RESULTS: There were 155 patients with CLE (mean ± SD age at diagnosis 48 ± 16 years, 65% female, mean ± SD BMI 26.3 ± 7.1 kg/m2 , 40% smokers, 9% with diabetes mellitus). During a median followup of 14.6 years, 41 CLE patients had cardiovascular events (15 patients with CVAs, 32 patients with IHD), with a 20-year cumulative incidence of 31.6%. As compared to non-CLE subjects, the risk of CVAs (smoking-adjusted hazard ratio [HR] 2.97 [95% confidence interval (95% CI) 1.13-7.78]) and PAD (HR 2.06 [95% CI 0.99-4.32]) was increased in patients with CLE, but the risk of IHD was not increased (HR 0.94 [95% CI 0.57-1.54]). There was no increase in cardiovascular mortality (HR 1.68 [95% CI 0.76-3.75]). The magnitude of risk for any cardiovascular outcome was not significantly influenced by the extent of cutaneous involvement.
CONCLUSION: CLE may be associated with an increased risk of CVAs and PAD, but not IHD. Factors contributing to increased CVA risk in patients with CLE merit evaluation.
© 2016, American College of Rheumatology.

Entities:  

Mesh:

Year:  2016        PMID: 27015109      PMCID: PMC5292935          DOI: 10.1002/acr.22892

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  23 in total

Review 1.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.

Authors:  T A Gooley; W Leisenring; J Crowley; B E Storer
Journal:  Stat Med       Date:  1999-03-30       Impact factor: 2.373

2.  Data resource profile: the Rochester Epidemiology Project (REP) medical records-linkage system.

Authors:  Jennifer L St Sauver; Brandon R Grossardt; Barbara P Yawn; L Joseph Melton; Joshua J Pankratz; Scott M Brue; Walter A Rocca
Journal:  Int J Epidemiol       Date:  2012-11-18       Impact factor: 7.196

Review 3.  Clinical manifestations of cutaneous lupus erythematosus.

Authors:  Victoria P Werth
Journal:  Autoimmun Rev       Date:  2005-02-10       Impact factor: 9.754

4.  Risk and predictors of cardiovascular disease in psoriasis: a population-based study.

Authors:  Hilal Maradit-Kremers; Ross A Dierkhising; Cynthia S Crowson; Murat Icen; Floranne C Ernste; Marian T McEvoy
Journal:  Int J Dermatol       Date:  2013-01       Impact factor: 2.736

5.  Use of a medical records linkage system to enumerate a dynamic population over time: the Rochester epidemiology project.

Authors:  Jennifer L St Sauver; Brandon R Grossardt; Barbara P Yawn; L Joseph Melton; Walter A Rocca
Journal:  Am J Epidemiol       Date:  2011-03-23       Impact factor: 4.897

6.  Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus.

Authors:  Mary J Roman; Beth-Ann Shanker; Adrienne Davis; Michael D Lockshin; Lisa Sammaritano; Ronit Simantov; Mary K Crow; Joseph E Schwartz; Stephen A Paget; Richard B Devereux; Jane E Salmon
Journal:  N Engl J Med       Date:  2003-12-18       Impact factor: 91.245

7.  Risk factors for development of coronary artery disease in women with systemic lupus erythematosus.

Authors:  Robert J Goldberg; Murray B Urowitz; Dominique Ibañez; Mandana Nikpour; Dafna D Gladman
Journal:  J Rheumatol       Date:  2009-10-15       Impact factor: 4.666

8.  Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors.

Authors:  Iben Marie Miller; Christina Ellervik; Shiva Yazdanyar; Gregor B E Jemec
Journal:  J Am Acad Dermatol       Date:  2013-12       Impact factor: 11.527

9.  Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses' health study.

Authors:  A Elisabeth Hak; Elizabeth W Karlson; Diane Feskanich; Meir J Stampfer; Karen H Costenbader
Journal:  Arthritis Rheum       Date:  2009-10-15

10.  Risk factors for coronary artery disease in patients with systemic lupus erythematosus.

Authors:  M Petri; S Perez-Gutthann; D Spence; M C Hochberg
Journal:  Am J Med       Date:  1992-11       Impact factor: 4.965

View more
  8 in total

1.  High Prevalence of Metabolic Syndrome in Patients with Discoid Lupus Erythematosus: A Cross-Sectional, Case-Control Study.

Authors:  Sevgi Akarsu; Ozlem Ozbagcivan; Fatma Semiz; Sebnem Aktan
Journal:  J Immunol Res       Date:  2017-01-03       Impact factor: 4.818

2.  CIRBP protects H9C2 cells against myocardial ischemia through inhibition of NF-κB pathway.

Authors:  T Y Long; R Jing; F Kuang; L Huang; Z X Qian; T L Yang
Journal:  Braz J Med Biol Res       Date:  2017-03-23       Impact factor: 2.590

3.  Therapeutic effect of vascular interventional therapy and aspirin combined with defibrase on cerebral ischemia in rats.

Authors:  Baoshan Li; Shouke Geng; Yuanli Dai
Journal:  Exp Ther Med       Date:  2018-06-07       Impact factor: 2.447

4.  Anti-Sm Antibody, Damage Index, and Corticosteroid Use Are Associated with Cardiac Involvement in Systemic Lupus Erythematosus: Data from a Prospective Registry Study.

Authors:  Jung Yoon Choe; Shin Seok Lee; Sang Gyu Kwak; Seong Kyu Kim
Journal:  J Korean Med Sci       Date:  2020-06-01       Impact factor: 2.153

Review 5.  Assessment and management of the heightened risk for atherosclerotic cardiovascular events in patients with lupus erythematosus or dermatomyositis.

Authors:  Emily Keyes; Madison Grinnell; Douglas Jacoby; Thomas Vazquez; DeAnna Diaz; Victoria P Werth; Kevin Jon Williams
Journal:  Int J Womens Dermatol       Date:  2021-09-09

Review 6.  Cardiovascular Disease-Associated Skin Conditions.

Authors:  Lia Hojman; Claudio Karsulovic
Journal:  Vasc Health Risk Manag       Date:  2022-02-16

Review 7.  The Burden of Living With Cutaneous Lupus Erythematosus.

Authors:  Cristina Drenkard; Kamil E Barbour; Kurt J Greenlund; S Sam Lim
Journal:  Front Med (Lausanne)       Date:  2022-08-08

Review 8.  Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management.

Authors:  Gerhard Rogler; Abha Singh; Arthur Kavanaugh; David T Rubin
Journal:  Gastroenterology       Date:  2021-08-03       Impact factor: 22.682

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.